Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

In its new incarnation, apecotrep has been shown to reduce protein in the urine (proteinuria) – a biomarker for kidney disease – in people with primary focal segmental glomerulosclerosis (FSGS), a ...

The Focal segmental glomerulosclerosis (FSGS) market report gives a thorough understanding of FSGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

DUBLIN--(BUSINESS WIRE)--The "Focal Segmental Glomerulosclerosis (FSGS) - Market Insights, Epidemiology, and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering ...

Please provide your email address to receive an email when new articles are posted on . Researchers identified functionally relevant risk factors for pediatric primary focal segmental ...

Travere said its responses are currently under agency review. ・FDA’s PDUFA target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis is January 13. ・The company expects U.

The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure. New findings from a team led by the University of Minnesota ...

Please provide your email address to receive an email when new articles are posted on . Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed ...

TOKYO, Oct. 17, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency ...